Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy

Anthony Khoo, Yi Zhong Zhuang, Karyn Boundy, Joseph Frasca

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Checkpoint inhibitor immunotherapy has revolutionized the treatment of metastatic cancer with new monoclonal antibodies exploiting novel therapeutic targets being developed at a rate commensurate with our increasing understanding of tumor immunobiology.
Atezolizumab is a humanized monoclonal antibody that binds to and inactivates programmed cell death ligand, a protein expressed on tumor cells which helps them avoid immune surveillance through binding to programmed cell death protein (PD-1) receptors on cytotoxic T-cells and thereby suppressing their activity.

Reactivating the antitumor immune response with atezolizumab can, however, result in the development of a range of immune-mediated treatment-related side effects, and a variety of nervous system disorders including peripheral neuropathy and myasthenia gravis have been described. Although the immune checkpoint inhibitors nivolumab and pembrolizumab that target PD-1 have been implicated in autoimmune myositis, this adverse event has not been well reported in atezolizumab, with only case previously described in the literature.
Original languageEnglish
Pages (from-to)E25-E26
Number of pages2
JournalNeurology: Clinical Practice
Issue number3
Early online date4 Feb 2019
Publication statusPublished - Jun 2019


  • Immunotherapy
  • Inhibitors
  • Metastatic cancer
  • Myositis
  • Case report


Dive into the research topics of 'Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy'. Together they form a unique fingerprint.

Cite this